Eli Lilly and Co (XSWX:LLY)
CHF 750 0 (0%) Market Cap: 661.33 Bil Enterprise Value: 685.18 Bil PE Ratio: 87.15 PB Ratio: 50.94 GF Score: 78/100

Eli Lilly and Co at Barclays Global Healthcare Conference Transcript

Mar 15, 2022 / 02:15PM GMT
Release Date Price: CHF216 (-28.00%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Okay. Good morning, and welcome to the Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst here at Barclays. It's good to see all of you in person today.

I'm pleased to welcome Lilly to the stage. We are [overweight] Eli Lilly and see a differentiated and compelling commercial portfolio and a pipeline with really attractive opportunities across metabolic health, neuro, oncology and immunology. Representing the company is Patrik Jonsson, President of Lilly Immunology, Lilly USA and Chief Customer Officer. Patrik, thank you very much for joining us.

Patrik Jonsson
Eli Lilly and Company - Senior VP, Chief Customer Officer, President of Lilly USA & President of Lilly Immunology

Thank you very much, Carter.

Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Great. So I think before we get into the Q&A, Patrik was just going to make some opening comments to kind of give

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot